API | otamixaban

otamixaban Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial. ^Wikipedia

Chemistry

SMILES: COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1
InChIKey: PFGVNLZDWRZPJW-OPAMFIHVSA-N
Mol. Mass: 446.51
ALogP: 2.42 Partition coefficient
ChEMBL Molecule:
otamixaban

More Chemistry

Pharmacology

Mechanism of Action:
- Coagulation factor X (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-(3-carbamimidoylbenzyl)-3-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester | 2-(r)-(3-carbamimidoylbenzyl)-3-(r)-(4-(1-oxypyridin-4-yl)benzoylamino)butyric acid methyl ester | fxv 673 | otamixaban

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Acute Coronary Syndrome (Phase 3)

Angioplasty, Balloon, Coronary (Phase 2)

Coronary Disease (Phase 2)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue